First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J. Davis, Janice M. Mehnert, Dana B. Cardin et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 93